Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2020-08-27 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
独立董事关于对公司关联方资金占用和对外担保的专项说明及独立意见
Audit Report / Information Classification · 95% confidence The document is a special statement and independent opinion by the independent directors of 瑞康医药集团股份有限公司 regarding related party fund occupation and external guarantees. It references regulatory notices and internal company systems related to controlling risks of fund occupation and guarantees. The document is a formal opinion and statement by independent directors, not a full audit report or annual report. It does not contain comprehensive financial data or audit results but rather a specific independent opinion on related party transactions and guarantees. This fits the category of Audit Report / Information (AR), which includes standalone audit reports, applied accounting principles, and results of internal or regulatory stress tests, excluding full annual reports. The document length is short (1064 characters), but it is not merely an announcement or certification; it contains substantive independent opinion content. Therefore, the best classification is AR with high confidence. H1 2020
2020-08-27 Chinese
第四届监事会第八次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement of the resolution passed by the Supervisory Board of Ruikang Pharmaceutical Group Co., Ltd. regarding the approval of the company's 2020 semi-annual report and its summary. It states that the report complies with relevant laws and regulations and reflects the company's operating status for the half-year period. The document is short (658 characters) and primarily serves as a formal announcement of the approval of the interim report rather than containing the report itself or detailed financial data. Therefore, it fits best as a Regulatory Filing (RNS) since it is an official disclosure related to the interim report but does not contain the report itself or substantive financial data.
2020-08-27 Chinese
2020年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "瑞康医药集团股份有限公司 2020 年半年度财务报告" which translates to "Ruikang Pharmaceutical Group Co., Ltd. 2020 Semi-Annual Financial Report." It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, notes on accounting policies, and other comprehensive financial data for the half-year period ending June 30, 2020. The document explicitly states it is a half-year report and includes substantive financial data and analysis, not just an announcement or summary. It is not an annual report (10-K) but an interim/quarterly report covering a period shorter than a full fiscal year. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2020
2020-08-27 Chinese
2020年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "瑞康医药集团股份有限公司 2020 年半年度报告全文" which translates to "Realcan Pharmaceutical Group Co., Ltd. 2020 Semi-Annual Report Full Text." It contains detailed financial data, business overview, management discussion and analysis, and other comprehensive information typical of an interim or quarterly report. The report period is clearly stated as January 1, 2020 to June 30, 2020, indicating it covers half a year. The document length is substantial (15,000 characters), and it includes actual financial statements and substantive financial data, not just an announcement or summary. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2020
2020-08-27 Chinese
第四届董事会第八次会议决议的公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the resolutions passed at the fourth board of directors' eighth meeting of Ruikang Pharmaceutical Group Co., Ltd. It specifically mentions the approval of the company's 2020 semi-annual report and its summary. The document is short (747 characters) and primarily serves to announce the board's approval of the interim report rather than containing the full financial statements or detailed analysis itself. It also includes voting results and confirms compliance with relevant laws. Therefore, this document is best classified as a Declaration of Voting Results & Voting Rights Announcements (DVA), since it reports the voting outcome on the interim report approval rather than the report itself.
2020-08-27 Chinese
国金证券股份有限公司关于公司2017年面向合格投资者公开发行公司债券（第一期）、2018年面向合格投资者公开发行公司债券（第一期）临时受托管理事务报告
Audit Report / Information Classification · 95% confidence The document is titled as a '临时受托管理事务报告' which translates to 'Temporary Trustee Management Affairs Report' related to bonds issued by 瑞康医药股份有限公司. It is prepared by 国金证券股份有限公司 as the trustee manager for bonds issued in 2017 and 2018. The content discusses regulatory warnings received by the issuer, the issuer's response, and risk reminders to investors. The document references regulatory rules and bond trustee management agreements. It does not contain full financial statements or detailed financial performance data but is a report on trustee management activities and regulatory compliance related to bond issuance. This fits the category of an Audit Report / Information (AR) as it is a standalone report related to regulatory and trustee oversight, not a full annual or interim report, nor an announcement or presentation. The document length is 2433 characters, which is sufficient for a report but not a brief announcement. Therefore, the best classification is AR with high confidence. FY 2019
2020-08-26 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.